First data for Lilly's RNA treatment for heart disease point to long-term durability in tiny group of patients
PHILADELPHIA — Eli Lilly’s investigational RNA silencing drug lowered levels of lipoprotein(a) in an early-stage study. Elevated levels of Lp(a) have been associated with a higher …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.